RealFeedApp PIONEER-ALS enrollment expands before efficacy data
VectorY Therapeutics expanded the PIONEER-ALS trial from 12 to 36 participants to test VTx-002, an antibody targeting TDP-43 protein aggregates found in 97% of patients.
- Field
- ageing and longevity
- What they did
- VectorY has increased the size of its ALS clinical trial from 12 to 36 participants to test the antibody therapy VTx-002 targeting the protein TDP-43.
- Why it matters
- The expansion occurred before any efficacy data was available to accelerate patient enrollment and activate trial sites globally.
#als#tdp-43#antibody therapy#clinical trial#vectory
